BiVictrix Therapeutics

BiVictrix Therapeutics Overview

Founded 2016
Founded
Status Private
Latest Deal Type Early Stage VC
Latest Deal Amount $222K
Latest Deal Amount
Investors 2

BiVictrix Therapeutics General Information

Description

Owner of a Pre-clinical drug development company intended to focus on developing and licensing novel, highly-selective, bispecific antibody-drug conjugates to target unmet medical needs in hematological and solid tumors. The company's proprietary technology platform enables the development of a new class of bispecific immunotherapeutics which exhibit improved potency together with a substantially wider therapeutic index, that is achieved through targeting proprietary antigen pairs which are exclusively expressed on the cancer cells but are absent from healthy cells, enabling medical community to optimize multiple therapeutic modalities.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Drug Delivery
Discovery Tools (Healthcare)
Primary Office
  • Bio Hub, Alderley Park
  • Cheshire
  • Alderley Edge SK10 4TG
  • England, United Kingdom

BiVictrix Therapeutics Timeline

2017201820192020
Financing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BiVictrix Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 01-Apr-2020 $222K 00.000 Completed Pre-Clinical Trials
3. Early Stage VC 01-Jul-2019 00000 00.000 00.00 Completed Pre-Clinical Trials
2. Seed Round 01-Jul-2018 $797K $1.36M 00.000 Completed Pre-Clinical Trials
1. Seed Round 30-Dec-2016 $563K $563K 00.000 Completed Pre-Clinical Trials

BiVictrix Therapeutics Cap Table

To view BiVictrix Therapeutics‘s complete cap table, request access »
Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 0,000 00.000000 000.00 000.00 00 000.00 0.000
Ordinary 00,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 24,157 $0.012672 $22.56 $22.56 1x $22.56 24.05%
Ordinary 29,961 $0.012672 $0.84 $0.84 1x $0.84 29.83%

BiVictrix Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
Tiffany Thorn Co-Founder & Chief Executive Officer
Patrick Molyneux Secretary
Patrick Molyneux Secretary

3 Former Executives

BiVictrix Therapeutics Board Members (5)

To view BiVictrix Therapeutics‘s full board member team, request access »
Name Representing Role Since
Michael Carter BiVictrix Therapeutics Board Member 000 0000
Norman Molyneux Acceleris Capital Chairman 000 0000

3 Former Board Members

BiVictrix Therapeutics Investors (2)

To view BiVictrix Therapeutics‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BioCity Accelerator/Incubator Minority 000 0000 000000 0
Development Bank of Wales Lender/Debt Provider Minority 000 0000 000000 0

Ready to get started?

Request a free trial